Certified by Founder
Lodge
Tubulis GmbH
start up
Germany
- Munich, Bayern
- 16/10/2025
- Series C
- $359,197,300
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
- Industry Biotechnology Research
- Website https://tubulis.com/
- LinkedIn https://www.linkedin.com/company/tubulis/
Integrate | $17,000,000 | (Feb 13, 2026)
daypass.com | $2,000,000 | (Feb 13, 2026)
CYDELPHI | $3,000,000 | (Feb 13, 2026)
Maestro Tech, Inc. | $1,200,000 | (Feb 13, 2026)
Ever | $31,000,000 | (Feb 13, 2026)
Manufact (formerly mcp-use) | $6,300,000 | (Feb 13, 2026)
Reflow | $15,000,000 | (Feb 13, 2026)
Santé(US) | $7,600,000 | (Feb 13, 2026)
Alva Energy | $33,000,000 | (Feb 13, 2026)
Project Omega | $12,000,000 | (Feb 13, 2026)
Brandlight | $30,000,000 | (Feb 12, 2026)
Inertia | $450,000,000 | (Feb 12, 2026)